Bempegaldesleukin
drugOn this page
Also known as Aldesleukin prodrug nktr-214BempegaldesleukinaBempegaldesleukineNktr 214Nktr-214NKTR-214 PRODRUG
Summary
Bempegaldesleukin (CHEMBL4298058) is a phase-3 clinical-stage protein targeting IL2RB; indicated across 13 conditions including melanoma and renal cell carcinoma.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Protein
- Targets: 1 (IL2RB)
- Indications: 13 conditions
- Clinical trials: 19
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4298058 |
| Name | Bempegaldesleukin |
| Type | Protein |
| Max phase | 3 |
Also known as: Aldesleukin prodrug nktr-214, Bempegaldesleukin, Bempegaldesleukina, Bempegaldesleukine, Nktr 214, Nktr-214, NKTR-214, NKTR-214 PRODRUG, BEMPEGALDESLEUKIN
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| IL2RB | Interleukin-2 receptor subunit β | Agonist | 5.75 | 0.1% | P14784 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): IL2RB.
Top Reactome pathways
4 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| RAF/MAP kinase cascade | 1 | IL2RB |
| Interleukin-15 signaling | 1 | IL2RB |
| Interleukin-2 signaling | 1 | IL2RB |
| Interleukin receptor SHC signaling | 1 | IL2RB |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| signal transduction | 1 |
| immunoglobulin mediated immune response | 1 |
| cytokine-mediated signaling pathway | 1 |
| interleukin-15-mediated signaling pathway | 1 |
| interleukin-2-mediated signaling pathway | 1 |
| negative regulation of apoptotic process | 1 |
| positive regulation of phagocytosis | 1 |
| protein-containing complex assembly | 1 |
| cell surface receptor signaling pathway | 1 |
Indications & clinical
Indications
13 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| melanoma | 3 | MONDO:0005105 | EFO:0000756 |
| renal cell carcinoma | 3 | MONDO:0005086 | EFO:0000681 |
| cutaneous melanoma | 3 | MONDO:0005012 | EFO:0000389 |
| metastatic melanoma | 3 | MONDO:0005191 | EFO:0002617 |
| sarcoma | 2 | MONDO:0005089 | EFO:0000691 |
| head and neck cancer | 2 | MONDO:0005627 | EFO:0006859 |
| neoplasm | 1 | MONDO:0005070 | EFO:0000616 |
| non-Hodgkin lymphoma | 1 | MONDO:0018908 | EFO:0005952 |
| severe acute respiratory syndrome | 1 | MONDO:0005091 | MONDO:0100096 |
| non-small cell lung carcinoma | 1 | MONDO:0005233 | EFO:0003060 |
3 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 19.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE1/PHASE2 | 6 |
| PHASE3 | 4 |
| PHASE2 | 4 |
| PHASE1 | 4 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03635983 | PHASE3 | COMPLETED | A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma |
| NCT03729245 | PHASE3 | TERMINATED | A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator’s Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC) |
| NCT04209114 | PHASE3 | COMPLETED | A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That May Have Invaded The Muscle Wall of the Bladder and Who Cannot Get Cisplatin, A Type of Medicine Given To Treat Bladder Cancer |
| NCT04410445 | PHASE3 | TERMINATED | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence |
| NCT04969861 | PHASE2/PHASE3 | TERMINATED | BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) |
| NCT03282344 | PHASE2 | ACTIVE_NOT_RECRUITING | A Study of NKTR-214 in Combination With Nivolumab in Patients With Metastatic and/or Locally Advanced Sarcoma |
| NCT07156643 | PHASE2 | NOT_YET_RECRUITING | A Prospective, Single-arm, Multicenter Exploratory Clinical Study of Anlotinib Combined With Bempegaldesleukin and Conventional Chemoradiotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Soft Tissue Sarcoma. |
| NCT02869295 | PHASE1/PHASE2 | COMPLETED | A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or Metastatic Solid Tumors |
| NCT03138889 | PHASE1/PHASE2 | TERMINATED | Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors |
| NCT03435640 | PHASE1/PHASE2 | TERMINATED | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metastatic Solid Tumor Malignancies |
| NCT03548467 | PHASE1/PHASE2 | COMPLETED | A Study to Evaluate Safety and Efficacy of Multiple Dosing With VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Cancer |
| NCT03785925 | PHASE2 | COMPLETED | A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Locally Advanced or Metastatic Urothelial Cancer |
| NCT04052204 | PHASE1/PHASE2 | TERMINATED | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors |
| NCT04730349 | PHASE1/PHASE2 | TERMINATED | A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer |
| NCT04936841 | PHASE2 | TERMINATED | Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma |
| NCT03745807 | PHASE1 | COMPLETED | An Investigational Study of NKTR-214 Combined With Nivolumab in Japanese Participants With Advanced Solid Tumors |
| NCT03772288 | PHASE1 | WITHDRAWN | A Study of TAK-659 in Combination With NKTR-214 in Participants With Advanced Non-Hodgkin Lymphoma (NHL) |
| NCT04646044 | PHASE1 | COMPLETED | A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild COVID-19 |
| NCT04955262 | PHASE1 | WITHDRAWN | A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Genes: IL2RB
- Diseases: melanoma, renal cell carcinoma, cutaneous melanoma, metastatic melanoma